¶ Cerebrotendinous Xanthomatosis (CTX)
¶ Introduction
Cerebrotendinous Xanthomatosis (Ctx) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
¶ Overview
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid storage disorder caused by mutations in the CYP27A1 gene, which encodes the mitochondrial enzyme sterol 27-hydroxylase. This enzyme deficiency disrupts bile acid synthesis, leading to pathological accumulation of cholestanol and cholesterol in tissues throughout the body, with particular predilection for the brain, tendons, lens, and vascular endothelium. CTX is uniquely significant among [neurodegenerative diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases because it is one of the few conditions in which neurodegeneration can be halted or even partially reversed with early treatment using chenodeoxycholic acid (CDCA) replacement therapy 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/) 2(https://link.springer.com/article/10.1007/s10545-017-0093-8).
First described by van Bogaert, Scherer, and Epstein in 1937, CTX is characterized by a progressive clinical course that begins with systemic manifestations in childhood (diarrhea, cataracts) and evolves into severe neurological disability (cerebellar ataxia, dementia, spastic paraparesis) if untreated. The diagnosis is frequently delayed by a median of 16 years from symptom onset, resulting in irreversible neurological damage that could have been prevented with timely intervention 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/) 3(https://ojrd.biomedcentral.com/articles/10.1186/s13023-014-0179-4).
¶ Epidemiology
CTX was originally considered an extremely rare disease, with only several hundred cases reported worldwide. However, population-based genetic studies suggest the true prevalence is significantly higher than clinically recognized, with estimated carrier frequencies varying substantially by ethnicity. Reported incidence estimates range from 1:134,970 to 1:461,358 in Europeans, 1:263,222 to 1:468,624 in Africans, 1:71,677 to 1:148,914 in Americans, 1:64,267 to 1:64,712 in East Asians, and 1:36,072 to 1:75,601 in South Asians. Higher prevalence has been documented in populations with increased consanguinity, such as the Druze community in Israel and Moroccan Jewish populations 2(https://link.springer.com/article/10.1007/s10545-017-0093-8) 4(https://www.ncbi.nlm.nih.gov/books/NBK564330/).
The disparity between genetic prevalence estimates and clinically diagnosed cases suggests that CTX is substantially underdiagnosed, likely due to its phenotypic heterogeneity and the fact that many of its early manifestations (diarrhea, cataracts) are common in the general population and not routinely associated with a metabolic etiology 2(https://link.springer.com/article/10.1007/s10545-017-0093-8).
¶ Genetics and Molecular Pathophysiology
¶ CYP27A1 Gene and Sterol 27-Hydroxylase
CTX is caused by biallelic loss-of-function mutations in the CYP27A1 gene located on chromosome 2q35. [The gene encodes sterol 27-hydroxylase, a mitochondrial cytochrome P450 enzyme with two essential functions in [cholesterol] metabolism: (1) the 27-hydroxylation of cholesterol intermediates in the alternative (acidic) pathway of bile acid synthesis, converting 5β-cholestane-3α,7α-diol to 5β-cholestane-3α,7α,27-triol, and (2) the side-chain oxidation of cholesterol to produce 27-hydroxycholesterol, a major mechanism for cholesterol elimination from peripheral tissues including the brain 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/) 3(https://ojrd.biomedcentral.com/articles/10.1186/s13023-014-0179-4).
Over 100 pathogenic CYP27A1 mutations have been identified, including missense mutations, nonsense mutations, splice-site variants, and small insertions/deletions. Genotype-phenotype correlations are limited, as clinical severity can vary even within families carrying the same mutation, suggesting modifying genetic and environmental factors 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/).
¶ Biochemical Consequences
Loss of sterol 27-hydroxylase activity produces a characteristic biochemical profile:
-
Impaired bile acid synthesis: Reduced production of chenodeoxycholic acid (CDCA) and cholic acid (CA). The decreased CDCA fails to provide negative feedback inhibition on cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis, leading to persistent pathway activation 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/).
-
Accumulation of bile alcohol intermediates: Cholesterol intermediates upstream of the enzymatic block (notably 7α-hydroxycholesterol) are shunted into alternative metabolic pathways, producing cholestanol (5α-cholestan-3β-ol) and bile alcohols (glucuronide conjugates detectable in urine) at markedly elevated levels 2(https://link.springer.com/article/10.1007/s10545-017-0093-8).
-
Cholestanol accumulation: Serum cholestanol levels rise to 5–10 times normal. Cholestanol is deposited in tissues throughout the body, reaching particularly high concentrations in tendons (xanthomas), lens (cataracts), and brain (neurodegeneration). In the brain, cholestanol can account for up to 50% of total sterols, compared to less than 0.5% normally 2(https://link.springer.com/article/10.1007/s10545-017-0093-8) 5(https://pmc.ncbi.nlm.nih.gov/articles/PMC8135047/).
-
27-hydroxycholesterol deficiency: Loss of 27-hydroxycholesterol, normally the dominant oxysterol in peripheral tissues and an important regulator of cholesterol homeostasis, impairs cholesterol efflux from peripheral cells and disrupts LXR signaling 5(https://pmc.ncbi.nlm.nih.gov/articles/PMC8135047/).
¶ Mechanisms of Neurodegeneration
The neurodegenerative process in CTX involves multiple pathways:
- Direct cholestanol toxicity: Cholestanol incorporation into neuronal membranes alters membrane fluidity, disrupts lipid raft organization, and impairs synaptic transmission and [dendritic spine] morphology 3(https://ojrd.biomedcentral.com/articles/10.1186/s13023-014-0179-4).
- Mitochondrial dysfunction: Cholestanol and bile acid intermediates directly inhibit mitochondrial respiratory chain complexes, leading to impaired energy metabolism and increased [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- production. This connects CTX to the broader mechanism of [oxidative stress in neurodegeneration[/mechanisms/[oxidative-stress-neurodegeneration[/mechanisms/[oxidative-stress-neurodegeneration[/mechanisms/[oxidative-stress-neurodegeneration--TEMP--/mechanisms)--FIX-- 3(https://ojrd.biomedcentral.com/articles/10.1186/s13023-014-0179-4).
- Myelin damage: Cholestanol replaces cholesterol in myelin sheaths, destabilizing myelin structure and causing progressive demyelination, particularly in the cerebellar white matter and corticospinal tracts 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/).
- neuroinflammation: Abnormal oxysterol profiles activate [microglial[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- inflammatory responses, contributing to secondary neuronal damage through [neuroinflammatory] mechanisms link.
- [apoptosis[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis--TEMP--/entities)--FIX--: Bile acid intermediates (7α-hydroxycholesterol, 7α-hydroxy-4-cholesten-3-one) are cytotoxic and promote [apoptotic] neuronal death through mitochondrial membrane permeabilization 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/).
¶ Clinical Manifestations
CTX follows a progressive course with diverse manifestations spanning multiple organ systems. The clinical presentation can be organized by age of onset 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/) 3(https://ojrd.biomedcentral.com/articles/10.1186/s13023-014-0179-4) 4(https://www.ncbi.nlm.nih.gov/books/NBK564330/):
¶ Infantile and Childhood Manifestations
- Neonatal cholestasis: Present in some cases, occasionally severe enough to mimic biliary atresia
- Chronic diarrhea: Often the earliest symptom, beginning in infancy; caused by bile acid malabsorption and frequently misdiagnosed as irritable bowel syndrome or food intolerance
- Bilateral cataracts: Juvenile-onset cataracts, typically diagnosed between ages 5–15 years; an important diagnostic clue, as idiopathic bilateral cataracts in young patients should prompt CTX screening
¶ Adolescent and Young Adult Manifestations
- Tendon xanthomas: Yellow-white lipid deposits most commonly affecting the Achilles tendons but also occurring in tibial tuberosities, triceps, and finger extensor tendons; present in approximately 70% of CTX patients
- Premature atherosclerosis: Accelerated cardiovascular disease due to cholestanol deposition in arterial walls
- Osteoporosis: Early-onset bone loss with increased fracture risk
¶ Adult Neurological Manifestations
Progressive neurological deterioration is the most debilitating aspect of CTX and typically dominates the clinical picture from the third decade onward (Nie et al., 2014):
- Cerebellar ataxia: Progressive gait and limb ataxia, the most common neurological feature; present in >80% of patients
- Pyramidal signs: Spastic paraparesis with hyperreflexia and extensor plantar responses
- Cognitive decline: Progressive dementia with subcortical pattern (executive dysfunction, slowed processing, personality changes); onset typically 30s-40s
- Psychiatric symptoms: Depression, behavioral disturbances, and psychosis may precede motor symptoms
- Peripheral neuropathy: Length-dependent sensorimotor neuropathy, predominantly axonal
- Seizures: Occur in approximately 10% of patients
- Parkinsonism: Rare but described, responsive to levodopa in some cases (Mignarri et al., 2014)
¶ Neuroimaging
¶ MRI Findings
Brain MRI abnormalities are present in approximately 84% of CTX patients and demonstrate characteristic patterns 6(https://www.sciencedirect.com/science/article/pii/S1930043325004753) 7(https://pmc.ncbi.nlm.nih.gov/articles/PMC3661428/):
- Cerebellar dentate nucleus signal changes: The most characteristic finding, present in approximately 79% of patients. Bilateral symmetric T2/FLAIR hyperintensity of the dentate nuclei and surrounding cerebellar white matter, representing demyelination and cholestanol deposition
- Cerebral white matter changes: Periventricular and deep white matter T2 hyperintensities, often symmetric, involving the posterior limbs of the internal capsules, cerebral peduncles, and corona radiata
- Basal ganglia involvement: T2 hyperintensity in the globus pallidus and substantia nigra
- Brainstem changes: Signal abnormalities in the pons (particularly anterior) and inferior olivary nuclei
- Cerebral and cerebellar atrophy: Progressive volume loss, particularly in the cerebellum
- Cerebellar vacuolation: A marker of disease progression and potentially poor therapeutic response
¶ MR Spectroscopy
Magnetic resonance spectroscopy (MRS) provides additional diagnostic information in CTX (Dotti et al., 2001):
- Reduced NAA/creatine ratio: Reflects neuronal loss and axonal damage in cerebellar and cerebral white matter
- Elevated lactate peak: Suggests mitochondrial dysfunction secondary to cholestanol toxicity, particularly in cerebellar dentate nuclei
- Elevated lipid peaks: May reflect active demyelination or cholestanol accumulation in affected white matter
- Clinical utility: MRS abnormalities can precede structural MRI changes, potentially serving as an early biomarker of disease activity and treatment response to chenodeoxycholic acid (CDCA)
- Monitoring: Serial MRS may help assess treatment efficacy by tracking normalization of metabolite ratios
¶ Diagnosis
¶ Biochemical Testing
The diagnosis of CTX relies on a combination of clinical suspicion and biochemical confirmation 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/) 2(https://link.springer.com/article/10.1007/s10545-017-0093-8):
- Serum cholestanol: Elevated 5–10 times above normal (>10 μg/mL; normal
.6 μg/mL). This is the most widely used screening test - Urinary bile alcohols: Markedly elevated glucuronide-conjugated bile alcohols, detectable by mass spectrometry
- Serum cholesterol: Normal or paradoxically low, in contrast to the marked elevation of cholestanol
- Serum bile acids: Reduced CDCA with increased ratio of cholic acid to CDCA
¶ Genetic Testing
Molecular genetic analysis of the CYP27A1 gene confirms the diagnosis and identifies the specific mutation(s). This is essential for genetic counseling and prenatal/preimplantation diagnosis. Whole exome or genome sequencing may identify CTX in patients with atypical presentations or when biochemical testing is equivocal 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/).
¶ Newborn Screening
There is growing interest in including CTX in newborn screening programs, as early treatment can prevent irreversible neurological damage. Cholestanol measurement in dried blood spots and bile alcohol detection by tandem mass spectrometry are feasible screening approaches under investigation 2(https://link.springer.com/article/10.1007/s10545-017-0093-8).
¶ Differential Diagnosis
The differential diagnosis of CTX varies by the presenting clinical features:
- Cataracts in children: Galactosemia, Lowe syndrome, congenital rubella, [Fabry disease[/diseases/[fabry-disease[/diseases/[fabry-disease[/diseases/[fabry-disease--TEMP--/diseases)--FIX--
- Tendon xanthomas: Familial hypercholesterolemia, sitosterolemia, [Gaucher disease[/diseases/[gaucher-disease[/diseases/[gaucher-disease[/diseases/[gaucher-disease--TEMP--/diseases)--FIX--
- Progressive ataxia: [Friedreich's Ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia--TEMP--/diseases)--FIX--, [spinocerebellar ataxias], [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX--, [Niemann-Pick type C[/diseases/[niemann-pick-type-c[/diseases/[niemann-pick-type-c[/diseases/[niemann-pick-type-c--TEMP--/diseases)--FIX--
- Young-onset dementia: [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [frontotemporal dementia[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, [metachromatic leukodystrophy[/diseases/[metachromatic-leukodystrophy[/diseases/[metachromatic-leukodystrophy[/diseases/[metachromatic-leukodystrophy--TEMP--/diseases)--FIX--, [adrenoleukodystrophy[/diseases/[adrenoleukodystrophy[/diseases/[adrenoleukodystrophy[/diseases/[adrenoleukodystrophy--TEMP--/diseases)--FIX--
- Spastic paraparesis: [Hereditary spastic paraplegia[/diseases/[hereditary-spastic-paraplegia[/diseases/[hereditary-spastic-paraplegia[/diseases/[hereditary-spastic-paraplegia--TEMP--/diseases)--FIX--, [primary lateral sclerosis[/diseases/[primary-lateral-sclerosis[/diseases/[primary-lateral-sclerosis[/diseases/[primary-lateral-sclerosis--TEMP--/diseases)--FIX--, [ALSP[/diseases/[alsp[/diseases/[alsp[/diseases/[alsp--TEMP--/diseases)--FIX--
¶ Treatment
¶ Chenodeoxycholic Acid (CDCA) Replacement
CDCA replacement therapy is the standard of care for CTX. CDCA provides negative feedback on CYP7A1, suppressing the overactive alternative bile acid synthesis pathway, normalizing serum cholestanol levels, reducing bile alcohol excretion, and halting or slowing neurological progression. Early treatment (before significant neurological involvement) can prevent neurodegeneration entirely, while treatment initiated after neurological symptoms can stabilize or partially improve function. The typical dose is 750 mg/day in adults (15 mg/kg/day in children), divided into three doses 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/) 2(https://link.springer.com/article/10.1007/s10545-017-0093-8) 3(https://ojrd.biomedcentral.com/articles/10.1186/s13023-014-0179-4).
Studies have demonstrated that brain DTI (diffusion tensor imaging) changes can be reversed with CDCA treatment, indicating recovery of white matter microstructure. Long-term MRI follow-up in treated patients shows stabilization of brain lesions and, in some cases, reduction in signal abnormalities 8(https://pubmed.ncbi.nlm.nih.gov/29260356/) 9(https://pubmed.ncbi.nlm.nih.gov/35918173/).
¶ HMG-CoA Reductase Inhibitors (Statins)
Statins reduce cholestanol synthesis by inhibiting HMG-CoA reductase and are used as adjunctive therapy alongside CDCA. They may further lower serum cholestanol levels and improve lipoprotein profiles, though they should not be used as monotherapy as they do not correct the underlying bile acid deficiency 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/).
¶ Emerging Therapies: Gene Therapy
[Gene therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy--TEMP--/treatments)--FIX-- using adeno-associated virus (AAV) vectors to deliver functional CYP27A1 is under preclinical development. AAV-mediated liver-directed gene therapy has demonstrated comprehensive and stable metabolic correction in animal models following a single vector administration, presenting a potential cure for CTX. Vivet Therapeutics (VTX-806) is developing an AAV gene therapy candidate for CTX 10(https://www.vivet-therapeutics.com/pipeline/vtx-806-cerebrotendinous-xanthomatosis/).
¶ Supportive Management
Additional supportive measures include surgical removal of visually significant cataracts, orthopedic management of tendon xanthomas, physiotherapy for spasticity and ataxia, antiepileptic drugs for seizures, psychiatric treatment as needed, and bone density monitoring with osteoporosis prevention 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC9816572/).
¶ Prognosis
The prognosis of CTX is highly dependent on the timing of diagnosis and treatment initiation. Patients treated before the onset of neurological symptoms can have a normal life expectancy and quality of life. Untreated patients typically develop progressive neurological disability, becoming wheelchair-dependent and developing severe dementia by the fourth or fifth decade. Death in untreated cases usually occurs from progressive neurological deterioration, cardiovascular complications, or respiratory failure related to bulbar dysfunction 2(https://link.springer.com/article/10.1007/s10545-017-0093-8) 3(https://ojrd.biomedcentral.com/articles/10.1186/s13023-014-0179-4).
¶ See Also
- [Gene Therapy for Neurodegenerative Diseases[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy--TEMP--/treatments)--FIX--
¶ Background
The study of Cerebrotendinous Xanthomatosis (Ctx) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ External Links
- PubMed - Biomedical literature
- Alzheimer's Disease Neuroimaging Initiative - Research data
- Allen Brain Atlas - Brain gene expression data
¶ References
- [Salen, G. et al. (2022]. Cerebrotendinous Xanthomatosis: A practice review of pathophysiology, diagnosis, and treatment. Frontiers in Neurology, 13, 1049850. PMC)
- [Salen, G. et al. (2017]. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). Journal of Inherited Metabolic Disease, 40(6), 771–781. DOI)
- [Nie, S. et al. (2014]. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet Journal of Rare Diseases, 9, 179. DOI)
- [Salen, G. et al. (2023]. Cerebrotendinous Xanthomatosis. StatPearls. NCBI)
- [Klinke, G. et al. (2021]. Metabolic profiling in serum, cerebrospinal fluid, and brain of patients with cerebrotendinous xanthomatosis. Journal of Lipid Research, 62, 100078. PMC)
- [Abadir, M. et al. (2025]. Cerebrotendinous xanthomatosis: A rare neurodegenerative disorder with characteristic imaging findings. Radiology Case Reports. DOI)
- [Barkhof, F. et al. (2013]. Cerebrotendinous xanthomatosis – The spectrum of imaging findings. PMC, PMC)
- [Chang, C.C. et al. (2018]. Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment. Journal of Clinical Lipidology, 12(1), 213–219. PubMed)
- [Mignarri, A. et al. (2022]. Long-term MRI Findings in Patients With Cerebrotendinous Xanthomatosis Treated With Chenodeoxycholic Acid. Neurology, 99(13), e1453–e1461. PubMed)
- [Vivet Therapeutics. VTX-806: Cerebrotendinous Xanthomatosis Gene Therapy. Website)
- [OMIM Entry #213700: Cerebrotendinous Xanthomatosis; CTX. OMIM)
- [National Organization for Rare Disorders (NORD]. Cerebrotendinous Xanthomatosis. NORD)